WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

*Meltem Turkmen, Sinan Dogan and Begum Basak

ABSTRACT

Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease whose pathogenesis is poorly understood. Adalimumab, is the only approved biological treatment for patients with HS, and some patients do not reach an optimal response, or experience a progressive response loss, needing therapeutic alternatives. Interleukin (IL)-23 is implicated in the pathogenesis of HS. Guselkumab is a monoclonal antibody targeting the p19 subunit of extracellular IL-23. Recently some authors have reported its effectiveness in patients with HS refractory to other systemic treatments. Objectives: The objective of this study is to evaluate the outcomes obtained with guselkumab treatment in ten patients with HS concomitantly with psoriasis. Methods: Ten patients with HS concomitantly with psoriasis who were receiving guselkumab monotherapy treatment for psoriasis at our dermatology unit were evaluated retrospectively. The primary efficacy end point was the proportion of the patients with a clinical response at week 24, defined according to the Hidradenitis Suppurativa Clinical Response (HiSCR). Results: Number of total nodules all the patients at the baseline and W24 were 10,6±2, 1; 43, 21±1, 2, respectively. Number of total abscesses at the baseline and W24 were 9, 4±3, 1; 2, 9±1, 3, respectively. Number of draining fistula at the baseline and W24 were 5, 3±2, 4; and 1, 82±1, 4, respectively. All patients reached Hidradenitis Suppurativa Clinical Response (HiSCR). Conclusion: Due to the promising results in these patients together with the observed good tolerability, we suggest that guselkumab may have a future role in the treatment of HS in the presence or absence of a concomitant psoriatic condition.

[Full Text Article] [Download Certificate]